https://www.selleckchem.com/products/Axitinib.html
With this cutoff value of 64 years, the occurrence of the primary end point was significantly lower in the ticagrelor monotherapy after 3-month DAPT group than in the ticagrelor-based 12-month DAPT group (4.4% versus 9.0%; P=0.002) in patients aged ≥64 years (n=1278), but it was not different in those aged less then 64 years (n=1778) with a significant interaction (P-interaction=0.036). Conclusions The age-dependent increase in the benefit of ticagrelor monotherapy after 3-month DAPT versus ticagrelor-based 12-month DAPT was observed i
Gefällt mir
Kommentar
Teilen
